Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3108743 - Capsule
LY3108743 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo - Healthy | PLACEBO_COMPARATOR | Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods. |
| LY3108743 - Healthy | EXPERIMENTAL | Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods. |
| Placebo - Diabetes | PLACEBO_COMPARATOR | Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods. |
| LY3108743 - Diabetes | EXPERIMENTAL | Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods. |
| Placebo - Solution | PLACEBO_COMPARATOR | Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods. |
| LY3108743 - Solution | EXPERIMENTAL | Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods. |
| Name | Type | Description |
|---|---|---|
| Placebo - Capsule | DRUG | Administered orally |
| LY3108743 - Capsule | DRUG | Administered orally |
| Placebo - Solution | DRUG | Administered orally |
| LY3108743 - Solution | DRUG | Administered orally |
Inclusion Criteria: * Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes * Have a body mass index (BMI) of 18.5 to 40.0 kilogram per square meter (kg/m\^2), inclusive, at screening * Have normal blood pressure * Participants w...
LY3108743 is an investigational small molecule developed by Eli Lilly and Company for type 2 diabetes mellitus. It has been studied in a Phase 1 clinical trial in healthy participants and participants with type 2 diabetes. It is not an approved medicine and remains in early clinical development.
LY3108743 is being developed for the treatment of type 2 diabetes mellitus, a metabolic condition. The only reported clinical study enrolled healthy participants and participants with type 2 diabetes. Because the program is at Phase 1, LY3108743 is investigational and has no approved use.
LY3108743 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in Singapore. No partner or licensing arrangement for LY3108743 is disclosed.
LY3108743 is in Phase 1. One Phase 1 trial has been completed, and no active trials are reported. The study was randomized, double blind, and placebo controlled, enrolling 44 participants. LY3108743 is investigational and has not been approved by the FDA.
LY3108743 has been evaluated in one completed Phase 1 trial, NCT01995656, titled A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes. It enrolled 44 participants in Singapore, aged 21 years and older, and included healthy volunteers. No active trials are reported.
Yes. LY3108743 - Capsule is an alternative name for LY3108743, referring to the capsule form of the investigational small molecule. Both names point to the same Eli Lilly and Company compound studied in Phase 1 for type 2 diabetes mellitus.